封面
市場調查報告書
商品編碼
1231285

高通量·篩檢(HTS)的全球市場

High Throughput Screening (HTS)

出版日期: | 出版商: Global Industry Analysts, Inc. | 英文 273 Pages | 商品交期: 最快1-2個工作天內

價格

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

高通量·篩檢(HTS)的全球市場到2030年將達到453億美元

在COVID-19後改變的商務環境中,2022年400億美元的高通量·篩檢(HTS)的全球市場,在2022年~2030年預計將以年複合成長率 完成1.6%的速度成長,2030年達到453億美元的規模。本報告所分析之市場區隔之一的消耗品/試劑將記錄年複合成長率5.2%,到分析期間結束時達到169億美元。考慮疫情後的復甦,儀器領域今後8年的年複合成長率將修正為-4.5%。

美國市場估算為112億美元,中國則將以年複合成長率6.9%增長

美國的高通量·篩檢(HTS)市場在2022年估算為達到112億美元。作為世界第2大經濟大國的中國,在2022年~2030年年複合成長率預計將為6.9%,2030年達到113億美元的市場規模。其他熱門的地區市場有日本和加拿大,在2022年~2030年預計將各以-6.9%,-4.5%的速度成長。在歐洲市場中,德國預計將以年複合成長率約-5.7%成長。

調查對像企業範例

  • Agilent Technologies, Inc.
  • Aurora Biomed Inc.
  • Axxam SpA
  • BD Biosciences
  • Beckman Coulter Inc.
  • Bio-Rad Laboratories Inc.
  • BioTek 儀器部門s Inc.
  • BMG LABTECH GmbH
  • Charles River Laboratories International Inc.
  • Corning Inc.
  • Danaher Corporation
  • Evotec AG
  • F. Hoffmann-La Roche Ltd.
  • Genedata AG
  • IntelliCyt(R)Corporation
  • Luminex Corporation
  • Molecular Devices Inc.
  • Pall ForteBio LLC
  • PerkinElmer Inc.
  • Sigma-Aldrich Corp.
  • Tecan Group Ltd.
  • Thermo Fischer Scientific Inc.

目錄

第1章 調查手法

第2章 摘要整理

  • 市場概要
  • 主要企業
  • 市場趨勢與推動因素
  • 全球市場預測

第3章 市場分析

  • 美國
  • 加拿大
  • 日本
  • 中國
  • 歐洲
  • 法國
  • 德國
  • 義大利
  • 英國
  • 西班牙
  • 俄羅斯
  • 其他歐洲
  • 亞太地區
  • 澳洲
  • 印度
  • 韓國
  • 其他亞太地區
  • 南美
  • 阿根廷
  • 巴西
簡介目錄
Product Code: MCP-6755

What`s New for 2023?

»Special coverage on Russia-Ukraine war; global inflation; easing of "zero-Covid" policy in China and its `bumpy` reopening; supply chain disruptions, global trade tensions; and risk of recession.

»Global competitiveness and key competitor percentage market shares

» Market presence across multiple geographies - Strong/Active/Niche/Trivial

»Online interactive peer-to-peer collaborative bespoke updates

»Access to our digital archives and MarketGlass Research Platform

»Complimentary updates for one year

Looking Ahead to 2023

The global economy is at a critical crossroads with a number of interlocking challenges and crises running in parallel. The uncertainty around how Russia`s war on Ukraine will play out this year and the war`s role in creating global instability means that the trouble on the inflation front is not over yet. Food and fuel inflation will remain a persistent economic problem. Higher retail inflation will impact consumer confidence and spending. As governments combat inflation by raising interest rates, new job creation will slowdown and impact economic activity and growth. Lower capital expenditure is in the offing as companies go slow on investments, held back by inflation worries and weaker demand. With slower growth and high inflation, developed markets seem primed to enter into a recession. Fears of new COVID outbreaks and China's already uncertain post-pandemic path poses a real risk of the world experiencing more acute supply chain pain and manufacturing disruptions this year. Volatile financial markets, growing trade tensions, stricter regulatory environment and pressure to mainstream climate change into economic decisions will compound the complexity of challenges faced. Year 2023 is expected to be tough year for most markets, investors and consumers. Nevertheless, there is always opportunity for businesses and their leaders who can chart a path forward with resilience and adaptability.

Global High Throughput Screening (HTS) Market to Reach $45.3 Billion by 2030

In the changed post COVID-19 business landscape, the global market for High Throughput Screening (HTS) estimated at US$40 Billion in the year 2022, is projected to reach a revised size of US$45.3 Billion by 2030, growing at aCAGR of 1.6% over the period 2022-2030. Consumables / Reagents, one of the segments analyzed in the report, is projected to record 5.2% CAGR and reach US$16.9 Billion by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Instruments segment is readjusted to a revised -4.5% CAGR for the next 8-year period.

The U.S. Market is Estimated at $11.2 Billion, While China is Forecast to Grow at 6.9% CAGR

The High Throughput Screening (HTS) market in the U.S. is estimated at US$11.2 Billion in the year 2022. China, the world`s second largest economy, is forecast to reach a projected market size of US$11.3 Billion by the year 2030 trailing a CAGR of 6.9% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at -6.9% and -4.5% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately -5.7% CAGR.

Select Competitors (Total 41 Featured):

  • Agilent Technologies, Inc.
  • Aurora Biomed Inc.
  • Axxam SpA
  • BD Biosciences
  • Beckman Coulter Inc.
  • Bio-Rad Laboratories Inc.
  • BioTek Instruments Inc.
  • BMG LABTECH GmbH
  • Charles River Laboratories International Inc.
  • Corning Inc.
  • Danaher Corporation
  • Evotec AG
  • F. Hoffmann-La Roche Ltd.
  • Genedata AG
  • IntelliCyt® Corporation
  • Luminex Corporation
  • Molecular Devices Inc.
  • Pall ForteBio LLC
  • PerkinElmer Inc.
  • Sigma-Aldrich Corp.
  • Tecan Group Ltd.
  • Thermo Fischer Scientific Inc.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • High Throughput Screening (HTS): A Prelude
    • Recent Market Activity
    • HTS: The Mainstream Technology for Drug Discovery Programs
    • Unparalleled Advantages in Compound Screening Drives Wider Adoption
    • Key Benefits of HTS - An Overview
    • Soaring R&D Spending Creates Conducive Environment for HTS
    • Shift towards High Throughput Research Builds Momentum for HTS
    • Upward Trajectory in Med Tech Sector Generates Parallel Opportunities
    • Stable Economic Outlook to Keep Market Sentiment Intact in the Near Term
    • Developed Regions: Key Revenue Contributors
    • HTS Adoption Continues to Expand in Developing Regions
    • Key Factors Driving Demand for HTS in the Developing Regions
    • Competitive Scenario
    • Leading Players in the World HTS Market
    • M&A Activity
    • High Throughput Screening (HTS) - Global Key Competitors Percentage Market Share in 2022 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2022 (E)
    • Impact of Covid-19 and a Looming Global Recession
  • 2. FOCUS ON SELECT PLAYERS
    • Agilent Technologies, Inc. (USA)
    • Aurora Biomed, Inc. (Canada)
    • Axxam SpA (Italy)
    • BD Biosciences (USA)
    • Danaher Corporation (USA)
    • Beckman Coulter, Inc. (USA)
    • Molecular Devices Inc. (USA)
    • Pall ForteBio LLC (USA)
    • Bio-Rad Laboratories, Inc. (USA)
    • BioTek Instruments Inc. (USA)
    • BMG LABTECH GmbH (Germany)
    • Charles River Laboratories International, Inc. (USA)
    • Corning Inc. (USA)
    • DiscoveRx Corporation (USA)
    • Evotec AG (Germany)
    • F. Hoffmann-La Roche Ltd. (Switzerland)
    • Genedata AG (Switzerland)
    • IntelliCyt® Corporation (USA)
    • Luminex Corporation (USA)
    • PerkinElmer, Inc. (USA)
    • Sigma-Aldrich Corp. (USA)
    • Tecan Group Ltd. (Switzerland)
    • Thermo Fisher Scientific Inc. (USA)
  • 3. MARKET TRENDS & DRIVERS
    • Cell-based Assay: The Widely Used HTS Technology
    • Resolving Technical Limitations: Cornerstone for Future Success of Cell-based HTS
    • HTS Aims to Expand Use Case in Biochemical Applications
    • Label-Free HTS Demonstrates Fastest Growth
    • Lab-on-a-Chip HTS Seeks to Proliferate the Market
    • Bioinformatics HTS Enhanced with Computational Algorithms
    • Positive Prognosis across End-Use Markets to Underpin Revenue Growth
    • Pharmaceutical Industry Leads the Way
    • HTS Deployments Soar in Academia
    • Progressive Advancements in HTS Instruments Accelerate Market Growth
    • Microplate Handling Systems: An Important HTS Instrument Type
    • Liquid Handling Devices: A Necessity in HTS Processes
    • Microscopic Systems Facilitate Seamless Quantitative Analysis
    • Advanced Software Platforms Augment HTS Proficiency
    • Services: An Important Revenue Generating Segment
    • Expansion in Compound Libraries Widens Functional Scope of HTS
    • Compound Libraries Facilitate Simultaneous Functional Genomics & Small Molecule Analysis
    • Laboratory Automation & Miniaturization Spell Opportunities for HTS
    • Miniaturization of Compound Screening Processes Drives Demand for HTS
    • HTS Miniaturization - Technology Developments
    • HTS Robotics Support Miniaturization
    • IVC - A Miniaturized, Powerful HTS Technology
    • HTS Assumes Critical Importance in Target Identification & Validation
    • HTS Gathers Steam in Primary Screening Applications
    • HTS Perceives Bright Future in Stem Cell Research
    • HTS in Kinase Inhibitors Identification
    • HTS in Alzheimer's Disease Drug Discovery
    • HTS for Less Simplified PCR Systems
    • HTFC Eases Metabolic Activity Analysis for Pharmaceutical Drugs
    • Open Access Platforms Widen HTS Audience Base
    • Need for Stringent QA System to Keep Failures at Bay
    • High Throughput Screening (HTS) Vs. High Content Screening (HCS)
    • Rise in Adoption of HCS Technology in HTS Laboratories
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Recent Past, Current & Future Analysis for High Throughput Screening (HTS) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 2: World Historic Review for High Throughput Screening (HTS) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 3: World 16-Year Perspective for High Throughput Screening (HTS) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2023 & 2030
    • TABLE 4: World Recent Past, Current & Future Analysis for Consumables/Reagents by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 5: World Historic Review for Consumables/Reagents by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 6: World 16-Year Perspective for Consumables/Reagents by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
    • TABLE 7: World Recent Past, Current & Future Analysis for Instruments by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 8: World Historic Review for Instruments by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 9: World 16-Year Perspective for Instruments by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
    • TABLE 10: World Recent Past, Current & Future Analysis for Software & Services by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 11: World Historic Review for Software & Services by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 12: World 16-Year Perspective for Software & Services by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
    • TABLE 13: World Recent Past, Current & Future Analysis for Cell-based Assay by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 14: World Historic Review for Cell-based Assay by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 15: World 16-Year Perspective for Cell-based Assay by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
    • TABLE 16: World Recent Past, Current & Future Analysis for Label-Free Technology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 17: World Historic Review for Label-Free Technology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 18: World 16-Year Perspective for Label-Free Technology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
    • TABLE 19: World Recent Past, Current & Future Analysis for Other Technologies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 20: World Historic Review for Other Technologies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 21: World 16-Year Perspective for Other Technologies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
    • TABLE 22: World Recent Past, Current & Future Analysis for Target Identification & Validation by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 23: World Historic Review for Target Identification & Validation by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 24: World 16-Year Perspective for Target Identification & Validation by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
    • TABLE 25: World Recent Past, Current & Future Analysis for Primary & Secondary Screening by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 26: World Historic Review for Primary & Secondary Screening by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 27: World 16-Year Perspective for Primary & Secondary Screening by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
    • TABLE 28: World Recent Past, Current & Future Analysis for Toxicology Assessment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 29: World Historic Review for Toxicology Assessment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 30: World 16-Year Perspective for Toxicology Assessment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
    • TABLE 31: World Recent Past, Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 32: World Historic Review for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 33: World 16-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
    • TABLE 34: World Recent Past, Current & Future Analysis for Pharmaceutical & Biotechnology Companies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 35: World Historic Review for Pharmaceutical & Biotechnology Companies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 36: World 16-Year Perspective for Pharmaceutical & Biotechnology Companies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
    • TABLE 37: World Recent Past, Current & Future Analysis for Academic & Government Institutes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 38: World Historic Review for Academic & Government Institutes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 39: World 16-Year Perspective for Academic & Government Institutes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
    • TABLE 40: World Recent Past, Current & Future Analysis for Contract Research Organizations (CRO) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 41: World Historic Review for Contract Research Organizations (CRO) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 42: World 16-Year Perspective for Contract Research Organizations (CRO) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
    • TABLE 43: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 44: World Historic Review for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 45: World 16-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
    • TABLE 46: World Recent Past, Current & Future Analysis for Consumables / Reagents by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 47: World Historic Review for Consumables / Reagents by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 48: World 16-Year Perspective for Consumables / Reagents by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
    • TABLE 49: World High Throughput Screening (HTS) Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • High Throughput Screening (HTS) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2023 (E)
    • TABLE 50: USA Recent Past, Current & Future Analysis for High Throughput Screening (HTS) by Product Type - Consumables / Reagents, Consumables/Reagents, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 51: USA Historic Review for High Throughput Screening (HTS) by Product Type - Consumables / Reagents, Consumables/Reagents, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 52: USA 16-Year Perspective for High Throughput Screening (HTS) by Product Type - Percentage Breakdown of Value Sales for Consumables / Reagents, Consumables/Reagents, Instruments and Software & Services for the Years 2014, 2023 & 2030
    • TABLE 53: USA Recent Past, Current & Future Analysis for High Throughput Screening (HTS) by Technology - Cell-based Assay, Label-Free Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 54: USA Historic Review for High Throughput Screening (HTS) by Technology - Cell-based Assay, Label-Free Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 55: USA 16-Year Perspective for High Throughput Screening (HTS) by Technology - Percentage Breakdown of Value Sales for Cell-based Assay, Label-Free Technology and Other Technologies for the Years 2014, 2023 & 2030
    • TABLE 56: USA Recent Past, Current & Future Analysis for High Throughput Screening (HTS) by Application - Target Identification & Validation, Primary & Secondary Screening, Toxicology Assessment and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 57: USA Historic Review for High Throughput Screening (HTS) by Application - Target Identification & Validation, Primary & Secondary Screening, Toxicology Assessment and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 58: USA 16-Year Perspective for High Throughput Screening (HTS) by Application - Percentage Breakdown of Value Sales for Target Identification & Validation, Primary & Secondary Screening, Toxicology Assessment and Other Applications for the Years 2014, 2023 & 2030
    • TABLE 59: USA Recent Past, Current & Future Analysis for High Throughput Screening (HTS) by End-Use - Pharmaceutical & Biotechnology Companies, Academic & Government Institutes, Contract Research Organizations (CRO) and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 60: USA Historic Review for High Throughput Screening (HTS) by End-Use - Pharmaceutical & Biotechnology Companies, Academic & Government Institutes, Contract Research Organizations (CRO) and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 61: USA 16-Year Perspective for High Throughput Screening (HTS) by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Biotechnology Companies, Academic & Government Institutes, Contract Research Organizations (CRO) and Other End-Uses for the Years 2014, 2023 & 2030
  • CANADA
    • TABLE 62: Canada Recent Past, Current & Future Analysis for High Throughput Screening (HTS) by Product Type - Consumables / Reagents, Consumables/Reagents, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 63: Canada Historic Review for High Throughput Screening (HTS) by Product Type - Consumables / Reagents, Consumables/Reagents, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 64: Canada 16-Year Perspective for High Throughput Screening (HTS) by Product Type - Percentage Breakdown of Value Sales for Consumables / Reagents, Consumables/Reagents, Instruments and Software & Services for the Years 2014, 2023 & 2030
    • TABLE 65: Canada Recent Past, Current & Future Analysis for High Throughput Screening (HTS) by Technology - Cell-based Assay, Label-Free Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 66: Canada Historic Review for High Throughput Screening (HTS) by Technology - Cell-based Assay, Label-Free Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 67: Canada 16-Year Perspective for High Throughput Screening (HTS) by Technology - Percentage Breakdown of Value Sales for Cell-based Assay, Label-Free Technology and Other Technologies for the Years 2014, 2023 & 2030
    • TABLE 68: Canada Recent Past, Current & Future Analysis for High Throughput Screening (HTS) by Application - Target Identification & Validation, Primary & Secondary Screening, Toxicology Assessment and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 69: Canada Historic Review for High Throughput Screening (HTS) by Application - Target Identification & Validation, Primary & Secondary Screening, Toxicology Assessment and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 70: Canada 16-Year Perspective for High Throughput Screening (HTS) by Application - Percentage Breakdown of Value Sales for Target Identification & Validation, Primary & Secondary Screening, Toxicology Assessment and Other Applications for the Years 2014, 2023 & 2030
    • TABLE 71: Canada Recent Past, Current & Future Analysis for High Throughput Screening (HTS) by End-Use - Pharmaceutical & Biotechnology Companies, Academic & Government Institutes, Contract Research Organizations (CRO) and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 72: Canada Historic Review for High Throughput Screening (HTS) by End-Use - Pharmaceutical & Biotechnology Companies, Academic & Government Institutes, Contract Research Organizations (CRO) and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 73: Canada 16-Year Perspective for High Throughput Screening (HTS) by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Biotechnology Companies, Academic & Government Institutes, Contract Research Organizations (CRO) and Other End-Uses for the Years 2014, 2023 & 2030
  • JAPAN
    • High Throughput Screening (HTS) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2023 (E)
    • TABLE 74: Japan Recent Past, Current & Future Analysis for High Throughput Screening (HTS) by Product Type - Consumables / Reagents, Consumables/Reagents, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 75: Japan Historic Review for High Throughput Screening (HTS) by Product Type - Consumables / Reagents, Consumables/Reagents, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 76: Japan 16-Year Perspective for High Throughput Screening (HTS) by Product Type - Percentage Breakdown of Value Sales for Consumables / Reagents, Consumables/Reagents, Instruments and Software & Services for the Years 2014, 2023 & 2030
    • TABLE 77: Japan Recent Past, Current & Future Analysis for High Throughput Screening (HTS) by Technology - Cell-based Assay, Label-Free Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 78: Japan Historic Review for High Throughput Screening (HTS) by Technology - Cell-based Assay, Label-Free Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 79: Japan 16-Year Perspective for High Throughput Screening (HTS) by Technology - Percentage Breakdown of Value Sales for Cell-based Assay, Label-Free Technology and Other Technologies for the Years 2014, 2023 & 2030
    • TABLE 80: Japan Recent Past, Current & Future Analysis for High Throughput Screening (HTS) by Application - Target Identification & Validation, Primary & Secondary Screening, Toxicology Assessment and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 81: Japan Historic Review for High Throughput Screening (HTS) by Application - Target Identification & Validation, Primary & Secondary Screening, Toxicology Assessment and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 82: Japan 16-Year Perspective for High Throughput Screening (HTS) by Application - Percentage Breakdown of Value Sales for Target Identification & Validation, Primary & Secondary Screening, Toxicology Assessment and Other Applications for the Years 2014, 2023 & 2030
    • TABLE 83: Japan Recent Past, Current & Future Analysis for High Throughput Screening (HTS) by End-Use - Pharmaceutical & Biotechnology Companies, Academic & Government Institutes, Contract Research Organizations (CRO) and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 84: Japan Historic Review for High Throughput Screening (HTS) by End-Use - Pharmaceutical & Biotechnology Companies, Academic & Government Institutes, Contract Research Organizations (CRO) and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 85: Japan 16-Year Perspective for High Throughput Screening (HTS) by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Biotechnology Companies, Academic & Government Institutes, Contract Research Organizations (CRO) and Other End-Uses for the Years 2014, 2023 & 2030
  • CHINA
    • High Throughput Screening (HTS) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2023 (E)
    • TABLE 86: China Recent Past, Current & Future Analysis for High Throughput Screening (HTS) by Product Type - Consumables / Reagents, Consumables/Reagents, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 87: China Historic Review for High Throughput Screening (HTS) by Product Type - Consumables / Reagents, Consumables/Reagents, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 88: China 16-Year Perspective for High Throughput Screening (HTS) by Product Type - Percentage Breakdown of Value Sales for Consumables / Reagents, Consumables/Reagents, Instruments and Software & Services for the Years 2014, 2023 & 2030
    • TABLE 89: China Recent Past, Current & Future Analysis for High Throughput Screening (HTS) by Technology - Cell-based Assay, Label-Free Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 90: China Historic Review for High Throughput Screening (HTS) by Technology - Cell-based Assay, Label-Free Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 91: China 16-Year Perspective for High Throughput Screening (HTS) by Technology - Percentage Breakdown of Value Sales for Cell-based Assay, Label-Free Technology and Other Technologies for the Years 2014, 2023 & 2030
    • TABLE 92: China Recent Past, Current & Future Analysis for High Throughput Screening (HTS) by Application - Target Identification & Validation, Primary & Secondary Screening, Toxicology Assessment and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 93: China Historic Review for High Throughput Screening (HTS) by Application - Target Identification & Validation, Primary & Secondary Screening, Toxicology Assessment and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 94: China 16-Year Perspective for High Throughput Screening (HTS) by Application - Percentage Breakdown of Value Sales for Target Identification & Validation, Primary & Secondary Screening, Toxicology Assessment and Other Applications for the Years 2014, 2023 & 2030
    • TABLE 95: China Recent Past, Current & Future Analysis for High Throughput Screening (HTS) by End-Use - Pharmaceutical & Biotechnology Companies, Academic & Government Institutes, Contract Research Organizations (CRO) and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 96: China Historic Review for High Throughput Screening (HTS) by End-Use - Pharmaceutical & Biotechnology Companies, Academic & Government Institutes, Contract Research Organizations (CRO) and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 97: China 16-Year Perspective for High Throughput Screening (HTS) by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Biotechnology Companies, Academic & Government Institutes, Contract Research Organizations (CRO) and Other End-Uses for the Years 2014, 2023 & 2030
  • EUROPE
    • High Throughput Screening (HTS) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2023 (E)
    • TABLE 98: Europe Recent Past, Current & Future Analysis for High Throughput Screening (HTS) by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 99: Europe Historic Review for High Throughput Screening (HTS) by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 100: Europe 16-Year Perspective for High Throughput Screening (HTS) by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2023 & 2030
    • TABLE 101: Europe Recent Past, Current & Future Analysis for High Throughput Screening (HTS) by Product Type - Consumables / Reagents, Consumables/Reagents, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 102: Europe Historic Review for High Throughput Screening (HTS) by Product Type - Consumables / Reagents, Consumables/Reagents, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 103: Europe 16-Year Perspective for High Throughput Screening (HTS) by Product Type - Percentage Breakdown of Value Sales for Consumables / Reagents, Consumables/Reagents, Instruments and Software & Services for the Years 2014, 2023 & 2030
    • TABLE 104: Europe Recent Past, Current & Future Analysis for High Throughput Screening (HTS) by Technology - Cell-based Assay, Label-Free Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 105: Europe Historic Review for High Throughput Screening (HTS) by Technology - Cell-based Assay, Label-Free Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 106: Europe 16-Year Perspective for High Throughput Screening (HTS) by Technology - Percentage Breakdown of Value Sales for Cell-based Assay, Label-Free Technology and Other Technologies for the Years 2014, 2023 & 2030
    • TABLE 107: Europe Recent Past, Current & Future Analysis for High Throughput Screening (HTS) by Application - Target Identification & Validation, Primary & Secondary Screening, Toxicology Assessment and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 108: Europe Historic Review for High Throughput Screening (HTS) by Application - Target Identification & Validation, Primary & Secondary Screening, Toxicology Assessment and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 109: Europe 16-Year Perspective for High Throughput Screening (HTS) by Application - Percentage Breakdown of Value Sales for Target Identification & Validation, Primary & Secondary Screening, Toxicology Assessment and Other Applications for the Years 2014, 2023 & 2030
    • TABLE 110: Europe Recent Past, Current & Future Analysis for High Throughput Screening (HTS) by End-Use - Pharmaceutical & Biotechnology Companies, Academic & Government Institutes, Contract Research Organizations (CRO) and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 111: Europe Historic Review for High Throughput Screening (HTS) by End-Use - Pharmaceutical & Biotechnology Companies, Academic & Government Institutes, Contract Research Organizations (CRO) and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 112: Europe 16-Year Perspective for High Throughput Screening (HTS) by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Biotechnology Companies, Academic & Government Institutes, Contract Research Organizations (CRO) and Other End-Uses for the Years 2014, 2023 & 2030
  • FRANCE
    • High Throughput Screening (HTS) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2023 (E)
    • TABLE 113: France Recent Past, Current & Future Analysis for High Throughput Screening (HTS) by Product Type - Consumables / Reagents, Consumables/Reagents, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 114: France Historic Review for High Throughput Screening (HTS) by Product Type - Consumables / Reagents, Consumables/Reagents, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 115: France 16-Year Perspective for High Throughput Screening (HTS) by Product Type - Percentage Breakdown of Value Sales for Consumables / Reagents, Consumables/Reagents, Instruments and Software & Services for the Years 2014, 2023 & 2030
    • TABLE 116: France Recent Past, Current & Future Analysis for High Throughput Screening (HTS) by Technology - Cell-based Assay, Label-Free Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 117: France Historic Review for High Throughput Screening (HTS) by Technology - Cell-based Assay, Label-Free Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 118: France 16-Year Perspective for High Throughput Screening (HTS) by Technology - Percentage Breakdown of Value Sales for Cell-based Assay, Label-Free Technology and Other Technologies for the Years 2014, 2023 & 2030
    • TABLE 119: France Recent Past, Current & Future Analysis for High Throughput Screening (HTS) by Application - Target Identification & Validation, Primary & Secondary Screening, Toxicology Assessment and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 120: France Historic Review for High Throughput Screening (HTS) by Application - Target Identification & Validation, Primary & Secondary Screening, Toxicology Assessment and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 121: France 16-Year Perspective for High Throughput Screening (HTS) by Application - Percentage Breakdown of Value Sales for Target Identification & Validation, Primary & Secondary Screening, Toxicology Assessment and Other Applications for the Years 2014, 2023 & 2030
    • TABLE 122: France Recent Past, Current & Future Analysis for High Throughput Screening (HTS) by End-Use - Pharmaceutical & Biotechnology Companies, Academic & Government Institutes, Contract Research Organizations (CRO) and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 123: France Historic Review for High Throughput Screening (HTS) by End-Use - Pharmaceutical & Biotechnology Companies, Academic & Government Institutes, Contract Research Organizations (CRO) and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 124: France 16-Year Perspective for High Throughput Screening (HTS) by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Biotechnology Companies, Academic & Government Institutes, Contract Research Organizations (CRO) and Other End-Uses for the Years 2014, 2023 & 2030
  • GERMANY
    • High Throughput Screening (HTS) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2023 (E)
    • TABLE 125: Germany Recent Past, Current & Future Analysis for High Throughput Screening (HTS) by Product Type - Consumables / Reagents, Consumables/Reagents, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 126: Germany Historic Review for High Throughput Screening (HTS) by Product Type - Consumables / Reagents, Consumables/Reagents, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 127: Germany 16-Year Perspective for High Throughput Screening (HTS) by Product Type - Percentage Breakdown of Value Sales for Consumables / Reagents, Consumables/Reagents, Instruments and Software & Services for the Years 2014, 2023 & 2030
    • TABLE 128: Germany Recent Past, Current & Future Analysis for High Throughput Screening (HTS) by Technology - Cell-based Assay, Label-Free Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 129: Germany Historic Review for High Throughput Screening (HTS) by Technology - Cell-based Assay, Label-Free Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 130: Germany 16-Year Perspective for High Throughput Screening (HTS) by Technology - Percentage Breakdown of Value Sales for Cell-based Assay, Label-Free Technology and Other Technologies for the Years 2014, 2023 & 2030
    • TABLE 131: Germany Recent Past, Current & Future Analysis for High Throughput Screening (HTS) by Application - Target Identification & Validation, Primary & Secondary Screening, Toxicology Assessment and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 132: Germany Historic Review for High Throughput Screening (HTS) by Application - Target Identification & Validation, Primary & Secondary Screening, Toxicology Assessment and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 133: Germany 16-Year Perspective for High Throughput Screening (HTS) by Application - Percentage Breakdown of Value Sales for Target Identification & Validation, Primary & Secondary Screening, Toxicology Assessment and Other Applications for the Years 2014, 2023 & 2030
    • TABLE 134: Germany Recent Past, Current & Future Analysis for High Throughput Screening (HTS) by End-Use - Pharmaceutical & Biotechnology Companies, Academic & Government Institutes, Contract Research Organizations (CRO) and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 135: Germany Historic Review for High Throughput Screening (HTS) by End-Use - Pharmaceutical & Biotechnology Companies, Academic & Government Institutes, Contract Research Organizations (CRO) and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 136: Germany 16-Year Perspective for High Throughput Screening (HTS) by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Biotechnology Companies, Academic & Government Institutes, Contract Research Organizations (CRO) and Other End-Uses for the Years 2014, 2023 & 2030
  • ITALY
    • TABLE 137: Italy Recent Past, Current & Future Analysis for High Throughput Screening (HTS) by Product Type - Consumables / Reagents, Consumables/Reagents, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 138: Italy Historic Review for High Throughput Screening (HTS) by Product Type - Consumables / Reagents, Consumables/Reagents, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 139: Italy 16-Year Perspective for High Throughput Screening (HTS) by Product Type - Percentage Breakdown of Value Sales for Consumables / Reagents, Consumables/Reagents, Instruments and Software & Services for the Years 2014, 2023 & 2030
    • TABLE 140: Italy Recent Past, Current & Future Analysis for High Throughput Screening (HTS) by Technology - Cell-based Assay, Label-Free Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 141: Italy Historic Review for High Throughput Screening (HTS) by Technology - Cell-based Assay, Label-Free Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 142: Italy 16-Year Perspective for High Throughput Screening (HTS) by Technology - Percentage Breakdown of Value Sales for Cell-based Assay, Label-Free Technology and Other Technologies for the Years 2014, 2023 & 2030
    • TABLE 143: Italy Recent Past, Current & Future Analysis for High Throughput Screening (HTS) by Application - Target Identification & Validation, Primary & Secondary Screening, Toxicology Assessment and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 144: Italy Historic Review for High Throughput Screening (HTS) by Application - Target Identification & Validation, Primary & Secondary Screening, Toxicology Assessment and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 145: Italy 16-Year Perspective for High Throughput Screening (HTS) by Application - Percentage Breakdown of Value Sales for Target Identification & Validation, Primary & Secondary Screening, Toxicology Assessment and Other Applications for the Years 2014, 2023 & 2030
    • TABLE 146: Italy Recent Past, Current & Future Analysis for High Throughput Screening (HTS) by End-Use - Pharmaceutical & Biotechnology Companies, Academic & Government Institutes, Contract Research Organizations (CRO) and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 147: Italy Historic Review for High Throughput Screening (HTS) by End-Use - Pharmaceutical & Biotechnology Companies, Academic & Government Institutes, Contract Research Organizations (CRO) and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 148: Italy 16-Year Perspective for High Throughput Screening (HTS) by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Biotechnology Companies, Academic & Government Institutes, Contract Research Organizations (CRO) and Other End-Uses for the Years 2014, 2023 & 2030
  • UNITED KINGDOM
    • High Throughput Screening (HTS) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2023 (E)
    • TABLE 149: UK Recent Past, Current & Future Analysis for High Throughput Screening (HTS) by Product Type - Consumables / Reagents, Consumables/Reagents, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 150: UK Historic Review for High Throughput Screening (HTS) by Product Type - Consumables / Reagents, Consumables/Reagents, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 151: UK 16-Year Perspective for High Throughput Screening (HTS) by Product Type - Percentage Breakdown of Value Sales for Consumables / Reagents, Consumables/Reagents, Instruments and Software & Services for the Years 2014, 2023 & 2030
    • TABLE 152: UK Recent Past, Current & Future Analysis for High Throughput Screening (HTS) by Technology - Cell-based Assay, Label-Free Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 153: UK Historic Review for High Throughput Screening (HTS) by Technology - Cell-based Assay, Label-Free Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 154: UK 16-Year Perspective for High Throughput Screening (HTS) by Technology - Percentage Breakdown of Value Sales for Cell-based Assay, Label-Free Technology and Other Technologies for the Years 2014, 2023 & 2030
    • TABLE 155: UK Recent Past, Current & Future Analysis for High Throughput Screening (HTS) by Application - Target Identification & Validation, Primary & Secondary Screening, Toxicology Assessment and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 156: UK Historic Review for High Throughput Screening (HTS) by Application - Target Identification & Validation, Primary & Secondary Screening, Toxicology Assessment and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 157: UK 16-Year Perspective for High Throughput Screening (HTS) by Application - Percentage Breakdown of Value Sales for Target Identification & Validation, Primary & Secondary Screening, Toxicology Assessment and Other Applications for the Years 2014, 2023 & 2030
    • TABLE 158: UK Recent Past, Current & Future Analysis for High Throughput Screening (HTS) by End-Use - Pharmaceutical & Biotechnology Companies, Academic & Government Institutes, Contract Research Organizations (CRO) and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 159: UK Historic Review for High Throughput Screening (HTS) by End-Use - Pharmaceutical & Biotechnology Companies, Academic & Government Institutes, Contract Research Organizations (CRO) and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 160: UK 16-Year Perspective for High Throughput Screening (HTS) by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Biotechnology Companies, Academic & Government Institutes, Contract Research Organizations (CRO) and Other End-Uses for the Years 2014, 2023 & 2030
  • SPAIN
    • TABLE 161: Spain Recent Past, Current & Future Analysis for High Throughput Screening (HTS) by Product Type - Consumables / Reagents, Consumables/Reagents, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 162: Spain Historic Review for High Throughput Screening (HTS) by Product Type - Consumables / Reagents, Consumables/Reagents, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 163: Spain 16-Year Perspective for High Throughput Screening (HTS) by Product Type - Percentage Breakdown of Value Sales for Consumables / Reagents, Consumables/Reagents, Instruments and Software & Services for the Years 2014, 2023 & 2030
    • TABLE 164: Spain Recent Past, Current & Future Analysis for High Throughput Screening (HTS) by Technology - Cell-based Assay, Label-Free Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 165: Spain Historic Review for High Throughput Screening (HTS) by Technology - Cell-based Assay, Label-Free Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 166: Spain 16-Year Perspective for High Throughput Screening (HTS) by Technology - Percentage Breakdown of Value Sales for Cell-based Assay, Label-Free Technology and Other Technologies for the Years 2014, 2023 & 2030
    • TABLE 167: Spain Recent Past, Current & Future Analysis for High Throughput Screening (HTS) by Application - Target Identification & Validation, Primary & Secondary Screening, Toxicology Assessment and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 168: Spain Historic Review for High Throughput Screening (HTS) by Application - Target Identification & Validation, Primary & Secondary Screening, Toxicology Assessment and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 169: Spain 16-Year Perspective for High Throughput Screening (HTS) by Application - Percentage Breakdown of Value Sales for Target Identification & Validation, Primary & Secondary Screening, Toxicology Assessment and Other Applications for the Years 2014, 2023 & 2030
    • TABLE 170: Spain Recent Past, Current & Future Analysis for High Throughput Screening (HTS) by End-Use - Pharmaceutical & Biotechnology Companies, Academic & Government Institutes, Contract Research Organizations (CRO) and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 171: Spain Historic Review for High Throughput Screening (HTS) by End-Use - Pharmaceutical & Biotechnology Companies, Academic & Government Institutes, Contract Research Organizations (CRO) and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 172: Spain 16-Year Perspective for High Throughput Screening (HTS) by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Biotechnology Companies, Academic & Government Institutes, Contract Research Organizations (CRO) and Other End-Uses for the Years 2014, 2023 & 2030
  • RUSSIA
    • TABLE 173: Russia Recent Past, Current & Future Analysis for High Throughput Screening (HTS) by Product Type - Consumables / Reagents, Consumables/Reagents, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 174: Russia Historic Review for High Throughput Screening (HTS) by Product Type - Consumables / Reagents, Consumables/Reagents, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 175: Russia 16-Year Perspective for High Throughput Screening (HTS) by Product Type - Percentage Breakdown of Value Sales for Consumables / Reagents, Consumables/Reagents, Instruments and Software & Services for the Years 2014, 2023 & 2030
    • TABLE 176: Russia Recent Past, Current & Future Analysis for High Throughput Screening (HTS) by Technology - Cell-based Assay, Label-Free Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 177: Russia Historic Review for High Throughput Screening (HTS) by Technology - Cell-based Assay, Label-Free Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 178: Russia 16-Year Perspective for High Throughput Screening (HTS) by Technology - Percentage Breakdown of Value Sales for Cell-based Assay, Label-Free Technology and Other Technologies for the Years 2014, 2023 & 2030
    • TABLE 179: Russia Recent Past, Current & Future Analysis for High Throughput Screening (HTS) by Application - Target Identification & Validation, Primary & Secondary Screening, Toxicology Assessment and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 180: Russia Historic Review for High Throughput Screening (HTS) by Application - Target Identification & Validation, Primary & Secondary Screening, Toxicology Assessment and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 181: Russia 16-Year Perspective for High Throughput Screening (HTS) by Application - Percentage Breakdown of Value Sales for Target Identification & Validation, Primary & Secondary Screening, Toxicology Assessment and Other Applications for the Years 2014, 2023 & 2030
    • TABLE 182: Russia Recent Past, Current & Future Analysis for High Throughput Screening (HTS) by End-Use - Pharmaceutical & Biotechnology Companies, Academic & Government Institutes, Contract Research Organizations (CRO) and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 183: Russia Historic Review for High Throughput Screening (HTS) by End-Use - Pharmaceutical & Biotechnology Companies, Academic & Government Institutes, Contract Research Organizations (CRO) and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 184: Russia 16-Year Perspective for High Throughput Screening (HTS) by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Biotechnology Companies, Academic & Government Institutes, Contract Research Organizations (CRO) and Other End-Uses for the Years 2014, 2023 & 2030
  • REST OF EUROPE
    • TABLE 185: Rest of Europe Recent Past, Current & Future Analysis for High Throughput Screening (HTS) by Product Type - Consumables / Reagents, Consumables/Reagents, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 186: Rest of Europe Historic Review for High Throughput Screening (HTS) by Product Type - Consumables / Reagents, Consumables/Reagents, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 187: Rest of Europe 16-Year Perspective for High Throughput Screening (HTS) by Product Type - Percentage Breakdown of Value Sales for Consumables / Reagents, Consumables/Reagents, Instruments and Software & Services for the Years 2014, 2023 & 2030
    • TABLE 188: Rest of Europe Recent Past, Current & Future Analysis for High Throughput Screening (HTS) by Technology - Cell-based Assay, Label-Free Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 189: Rest of Europe Historic Review for High Throughput Screening (HTS) by Technology - Cell-based Assay, Label-Free Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 190: Rest of Europe 16-Year Perspective for High Throughput Screening (HTS) by Technology - Percentage Breakdown of Value Sales for Cell-based Assay, Label-Free Technology and Other Technologies for the Years 2014, 2023 & 2030
    • TABLE 191: Rest of Europe Recent Past, Current & Future Analysis for High Throughput Screening (HTS) by Application - Target Identification & Validation, Primary & Secondary Screening, Toxicology Assessment and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 192: Rest of Europe Historic Review for High Throughput Screening (HTS) by Application - Target Identification & Validation, Primary & Secondary Screening, Toxicology Assessment and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 193: Rest of Europe 16-Year Perspective for High Throughput Screening (HTS) by Application - Percentage Breakdown of Value Sales for Target Identification & Validation, Primary & Secondary Screening, Toxicology Assessment and Other Applications for the Years 2014, 2023 & 2030
    • TABLE 194: Rest of Europe Recent Past, Current & Future Analysis for High Throughput Screening (HTS) by End-Use - Pharmaceutical & Biotechnology Companies, Academic & Government Institutes, Contract Research Organizations (CRO) and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 195: Rest of Europe Historic Review for High Throughput Screening (HTS) by End-Use - Pharmaceutical & Biotechnology Companies, Academic & Government Institutes, Contract Research Organizations (CRO) and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 196: Rest of Europe 16-Year Perspective for High Throughput Screening (HTS) by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Biotechnology Companies, Academic & Government Institutes, Contract Research Organizations (CRO) and Other End-Uses for the Years 2014, 2023 & 2030
  • ASIA-PACIFIC
    • High Throughput Screening (HTS) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2023 (E)
    • TABLE 197: Asia-Pacific Recent Past, Current & Future Analysis for High Throughput Screening (HTS) by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 198: Asia-Pacific Historic Review for High Throughput Screening (HTS) by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 199: Asia-Pacific 16-Year Perspective for High Throughput Screening (HTS) by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2023 & 2030
    • TABLE 200: Asia-Pacific Recent Past, Current & Future Analysis for High Throughput Screening (HTS) by Product Type - Consumables / Reagents, Consumables/Reagents, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 201: Asia-Pacific Historic Review for High Throughput Screening (HTS) by Product Type - Consumables / Reagents, Consumables/Reagents, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 202: Asia-Pacific 16-Year Perspective for High Throughput Screening (HTS) by Product Type - Percentage Breakdown of Value Sales for Consumables / Reagents, Consumables/Reagents, Instruments and Software & Services for the Years 2014, 2023 & 2030
    • TABLE 203: Asia-Pacific Recent Past, Current & Future Analysis for High Throughput Screening (HTS) by Technology - Cell-based Assay, Label-Free Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 204: Asia-Pacific Historic Review for High Throughput Screening (HTS) by Technology - Cell-based Assay, Label-Free Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 205: Asia-Pacific 16-Year Perspective for High Throughput Screening (HTS) by Technology - Percentage Breakdown of Value Sales for Cell-based Assay, Label-Free Technology and Other Technologies for the Years 2014, 2023 & 2030
    • TABLE 206: Asia-Pacific Recent Past, Current & Future Analysis for High Throughput Screening (HTS) by Application - Target Identification & Validation, Primary & Secondary Screening, Toxicology Assessment and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 207: Asia-Pacific Historic Review for High Throughput Screening (HTS) by Application - Target Identification & Validation, Primary & Secondary Screening, Toxicology Assessment and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 208: Asia-Pacific 16-Year Perspective for High Throughput Screening (HTS) by Application - Percentage Breakdown of Value Sales for Target Identification & Validation, Primary & Secondary Screening, Toxicology Assessment and Other Applications for the Years 2014, 2023 & 2030
    • TABLE 209: Asia-Pacific Recent Past, Current & Future Analysis for High Throughput Screening (HTS) by End-Use - Pharmaceutical & Biotechnology Companies, Academic & Government Institutes, Contract Research Organizations (CRO) and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 210: Asia-Pacific Historic Review for High Throughput Screening (HTS) by End-Use - Pharmaceutical & Biotechnology Companies, Academic & Government Institutes, Contract Research Organizations (CRO) and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 211: Asia-Pacific 16-Year Perspective for High Throughput Screening (HTS) by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Biotechnology Companies, Academic & Government Institutes, Contract Research Organizations (CRO) and Other End-Uses for the Years 2014, 2023 & 2030
  • AUSTRALIA
    • High Throughput Screening (HTS) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2023 (E)
    • TABLE 212: Australia Recent Past, Current & Future Analysis for High Throughput Screening (HTS) by Product Type - Consumables / Reagents, Consumables/Reagents, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 213: Australia Historic Review for High Throughput Screening (HTS) by Product Type - Consumables / Reagents, Consumables/Reagents, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 214: Australia 16-Year Perspective for High Throughput Screening (HTS) by Product Type - Percentage Breakdown of Value Sales for Consumables / Reagents, Consumables/Reagents, Instruments and Software & Services for the Years 2014, 2023 & 2030
    • TABLE 215: Australia Recent Past, Current & Future Analysis for High Throughput Screening (HTS) by Technology - Cell-based Assay, Label-Free Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 216: Australia Historic Review for High Throughput Screening (HTS) by Technology - Cell-based Assay, Label-Free Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 217: Australia 16-Year Perspective for High Throughput Screening (HTS) by Technology - Percentage Breakdown of Value Sales for Cell-based Assay, Label-Free Technology and Other Technologies for the Years 2014, 2023 & 2030
    • TABLE 218: Australia Recent Past, Current & Future Analysis for High Throughput Screening (HTS) by Application - Target Identification & Validation, Primary & Secondary Screening, Toxicology Assessment and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 219: Australia Historic Review for High Throughput Screening (HTS) by Application - Target Identification & Validation, Primary & Secondary Screening, Toxicology Assessment and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 220: Australia 16-Year Perspective for High Throughput Screening (HTS) by Application - Percentage Breakdown of Value Sales for Target Identification & Validation, Primary & Secondary Screening, Toxicology Assessment and Other Applications for the Years 2014, 2023 & 2030
    • TABLE 221: Australia Recent Past, Current & Future Analysis for High Throughput Screening (HTS) by End-Use - Pharmaceutical & Biotechnology Companies, Academic & Government Institutes, Contract Research Organizations (CRO) and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 222: Australia Historic Review for High Throughput Screening (HTS) by End-Use - Pharmaceutical & Biotechnology Companies, Academic & Government Institutes, Contract Research Organizations (CRO) and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 223: Australia 16-Year Perspective for High Throughput Screening (HTS) by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Biotechnology Companies, Academic & Government Institutes, Contract Research Organizations (CRO) and Other End-Uses for the Years 2014, 2023 & 2030
  • INDIA
    • High Throughput Screening (HTS) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2023 (E)
    • TABLE 224: India Recent Past, Current & Future Analysis for High Throughput Screening (HTS) by Product Type - Consumables / Reagents, Consumables/Reagents, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 225: India Historic Review for High Throughput Screening (HTS) by Product Type - Consumables / Reagents, Consumables/Reagents, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 226: India 16-Year Perspective for High Throughput Screening (HTS) by Product Type - Percentage Breakdown of Value Sales for Consumables / Reagents, Consumables/Reagents, Instruments and Software & Services for the Years 2014, 2023 & 2030
    • TABLE 227: India Recent Past, Current & Future Analysis for High Throughput Screening (HTS) by Technology - Cell-based Assay, Label-Free Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 228: India Historic Review for High Throughput Screening (HTS) by Technology - Cell-based Assay, Label-Free Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 229: India 16-Year Perspective for High Throughput Screening (HTS) by Technology - Percentage Breakdown of Value Sales for Cell-based Assay, Label-Free Technology and Other Technologies for the Years 2014, 2023 & 2030
    • TABLE 230: India Recent Past, Current & Future Analysis for High Throughput Screening (HTS) by Application - Target Identification & Validation, Primary & Secondary Screening, Toxicology Assessment and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 231: India Historic Review for High Throughput Screening (HTS) by Application - Target Identification & Validation, Primary & Secondary Screening, Toxicology Assessment and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 232: India 16-Year Perspective for High Throughput Screening (HTS) by Application - Percentage Breakdown of Value Sales for Target Identification & Validation, Primary & Secondary Screening, Toxicology Assessment and Other Applications for the Years 2014, 2023 & 2030
    • TABLE 233: India Recent Past, Current & Future Analysis for High Throughput Screening (HTS) by End-Use - Pharmaceutical & Biotechnology Companies, Academic & Government Institutes, Contract Research Organizations (CRO) and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 234: India Historic Review for High Throughput Screening (HTS) by End-Use - Pharmaceutical & Biotechnology Companies, Academic & Government Institutes, Contract Research Organizations (CRO) and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 235: India 16-Year Perspective for High Throughput Screening (HTS) by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Biotechnology Companies, Academic & Government Institutes, Contract Research Organizations (CRO) and Other End-Uses for the Years 2014, 2023 & 2030
  • SOUTH KOREA
    • TABLE 236: South Korea Recent Past, Current & Future Analysis for High Throughput Screening (HTS) by Product Type - Consumables / Reagents, Consumables/Reagents, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 237: South Korea Historic Review for High Throughput Screening (HTS) by Product Type - Consumables / Reagents, Consumables/Reagents, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 238: South Korea 16-Year Perspective for High Throughput Screening (HTS) by Product Type - Percentage Breakdown of Value Sales for Consumables / Reagents, Consumables/Reagents, Instruments and Software & Services for the Years 2014, 2023 & 2030
    • TABLE 239: South Korea Recent Past, Current & Future Analysis for High Throughput Screening (HTS) by Technology - Cell-based Assay, Label-Free Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 240: South Korea Historic Review for High Throughput Screening (HTS) by Technology - Cell-based Assay, Label-Free Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 241: South Korea 16-Year Perspective for High Throughput Screening (HTS) by Technology - Percentage Breakdown of Value Sales for Cell-based Assay, Label-Free Technology and Other Technologies for the Years 2014, 2023 & 2030
    • TABLE 242: South Korea Recent Past, Current & Future Analysis for High Throughput Screening (HTS) by Application - Target Identification & Validation, Primary & Secondary Screening, Toxicology Assessment and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 243: South Korea Historic Review for High Throughput Screening (HTS) by Application - Target Identification & Validation, Primary & Secondary Screening, Toxicology Assessment and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 244: South Korea 16-Year Perspective for High Throughput Screening (HTS) by Application - Percentage Breakdown of Value Sales for Target Identification & Validation, Primary & Secondary Screening, Toxicology Assessment and Other Applications for the Years 2014, 2023 & 2030
    • TABLE 245: South Korea Recent Past, Current & Future Analysis for High Throughput Screening (HTS) by End-Use - Pharmaceutical & Biotechnology Companies, Academic & Government Institutes, Contract Research Organizations (CRO) and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 246: South Korea Historic Review for High Throughput Screening (HTS) by End-Use - Pharmaceutical & Biotechnology Companies, Academic & Government Institutes, Contract Research Organizations (CRO) and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 247: South Korea 16-Year Perspective for High Throughput Screening (HTS) by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Biotechnology Companies, Academic & Government Institutes, Contract Research Organizations (CRO) and Other End-Uses for the Years 2014, 2023 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 248: Rest of Asia-Pacific Recent Past, Current & Future Analysis for High Throughput Screening (HTS) by Product Type - Consumables / Reagents, Consumables/Reagents, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 249: Rest of Asia-Pacific Historic Review for High Throughput Screening (HTS) by Product Type - Consumables / Reagents, Consumables/Reagents, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 250: Rest of Asia-Pacific 16-Year Perspective for High Throughput Screening (HTS) by Product Type - Percentage Breakdown of Value Sales for Consumables / Reagents, Consumables/Reagents, Instruments and Software & Services for the Years 2014, 2023 & 2030
    • TABLE 251: Rest of Asia-Pacific Recent Past, Current & Future Analysis for High Throughput Screening (HTS) by Technology - Cell-based Assay, Label-Free Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 252: Rest of Asia-Pacific Historic Review for High Throughput Screening (HTS) by Technology - Cell-based Assay, Label-Free Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 253: Rest of Asia-Pacific 16-Year Perspective for High Throughput Screening (HTS) by Technology - Percentage Breakdown of Value Sales for Cell-based Assay, Label-Free Technology and Other Technologies for the Years 2014, 2023 & 2030
    • TABLE 254: Rest of Asia-Pacific Recent Past, Current & Future Analysis for High Throughput Screening (HTS) by Application - Target Identification & Validation, Primary & Secondary Screening, Toxicology Assessment and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 255: Rest of Asia-Pacific Historic Review for High Throughput Screening (HTS) by Application - Target Identification & Validation, Primary & Secondary Screening, Toxicology Assessment and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 256: Rest of Asia-Pacific 16-Year Perspective for High Throughput Screening (HTS) by Application - Percentage Breakdown of Value Sales for Target Identification & Validation, Primary & Secondary Screening, Toxicology Assessment and Other Applications for the Years 2014, 2023 & 2030
    • TABLE 257: Rest of Asia-Pacific Recent Past, Current & Future Analysis for High Throughput Screening (HTS) by End-Use - Pharmaceutical & Biotechnology Companies, Academic & Government Institutes, Contract Research Organizations (CRO) and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 258: Rest of Asia-Pacific Historic Review for High Throughput Screening (HTS) by End-Use - Pharmaceutical & Biotechnology Companies, Academic & Government Institutes, Contract Research Organizations (CRO) and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 259: Rest of Asia-Pacific 16-Year Perspective for High Throughput Screening (HTS) by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Biotechnology Companies, Academic & Government Institutes, Contract Research Organizations (CRO) and Other End-Uses for the Years 2014, 2023 & 2030
  • LATIN AMERICA
    • High Throughput Screening (HTS) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2023 (E)
    • TABLE 260: Latin America Recent Past, Current & Future Analysis for High Throughput Screening (HTS) by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 261: Latin America Historic Review for High Throughput Screening (HTS) by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 262: Latin America 16-Year Perspective for High Throughput Screening (HTS) by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2023 & 2030
    • TABLE 263: Latin America Recent Past, Current & Future Analysis for High Throughput Screening (HTS) by Product Type - Consumables / Reagents, Consumables/Reagents, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 264: Latin America Historic Review for High Throughput Screening (HTS) by Product Type - Consumables / Reagents, Consumables/Reagents, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 265: Latin America 16-Year Perspective for High Throughput Screening (HTS) by Product Type - Percentage Breakdown of Value Sales for Consumables / Reagents, Consumables/Reagents, Instruments and Software & Services for the Years 2014, 2023 & 2030
    • TABLE 266: Latin America Recent Past, Current & Future Analysis for High Throughput Screening (HTS) by Technology - Cell-based Assay, Label-Free Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 267: Latin America Historic Review for High Throughput Screening (HTS) by Technology - Cell-based Assay, Label-Free Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 268: Latin America 16-Year Perspective for High Throughput Screening (HTS) by Technology - Percentage Breakdown of Value Sales for Cell-based Assay, Label-Free Technology and Other Technologies for the Years 2014, 2023 & 2030
    • TABLE 269: Latin America Recent Past, Current & Future Analysis for High Throughput Screening (HTS) by Application - Target Identification & Validation, Primary & Secondary Screening, Toxicology Assessment and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 270: Latin America Historic Review for High Throughput Screening (HTS) by Application - Target Identification & Validation, Primary & Secondary Screening, Toxicology Assessment and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 271: Latin America 16-Year Perspective for High Throughput Screening (HTS) by Application - Percentage Breakdown of Value Sales for Target Identification & Validation, Primary & Secondary Screening, Toxicology Assessment and Other Applications for the Years 2014, 2023 & 2030
    • TABLE 272: Latin America Recent Past, Current & Future Analysis for High Throughput Screening (HTS) by End-Use - Pharmaceutical & Biotechnology Companies, Academic & Government Institutes, Contract Research Organizations (CRO) and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 273: Latin America Historic Review for High Throughput Screening (HTS) by End-Use - Pharmaceutical & Biotechnology Companies, Academic & Government Institutes, Contract Research Organizations (CRO) and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 274: Latin America 16-Year Perspective for High Throughput Screening (HTS) by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Biotechnology Companies, Academic & Government Institutes, Contract Research Organizations (CRO) and Other End-Uses for the Years 2014, 2023 & 2030
  • ARGENTINA
    • TABLE 275: Argentina Recent Past, Current & Future Analysis for High Throughput Screening (HTS) by Product Type - Consumables / Reagents, Consumables/Reagents, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 276: Argentina Historic Review for High Throughput Screening (HTS) by Product Type - Consumables / Reagents, Consumables/Reagents, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 277: Argentina 16-Year Perspective for High Throughput Screening (HTS) by Product Type - Percentage Breakdown of Value Sales for Consumables / Reagents, Consumables/Reagents, Instruments and Software & Services for the Years 2014, 2023 & 2030
    • TABLE 278: Argentina Recent Past, Current & Future Analysis for High Throughput Screening (HTS) by Technology - Cell-based Assay, Label-Free Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 279: Argentina Historic Review for High Throughput Screening (HTS) by Technology - Cell-based Assay, Label-Free Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 280: Argentina 16-Year Perspective for High Throughput Screening (HTS) by Technology - Percentage Breakdown of Value Sales for Cell-based Assay, Label-Free Technology and Other Technologies for the Years 2014, 2023 & 2030
    • TABLE 281: Argentina Recent Past, Current & Future Analysis for High Throughput Screening (HTS) by Application - Target Identification & Validation, Primary & Secondary Screening, Toxicology Assessment and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 282: Argentina Historic Review for High Throughput Screening (HTS) by Application - Target Identification & Validation, Primary & Secondary Screening, Toxicology Assessment and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 283: Argentina 16-Year Perspective for High Throughput Screening (HTS) by Application - Percentage Breakdown of Value Sales for Target Identification & Validation, Primary & Secondary Screening, Toxicology Assessment and Other Applications for the Years 2014, 2023 & 2030
    • TABLE 284: Argentina Recent Past, Current & Future Analysis for High Throughput Screening (HTS) by End-Use - Pharmaceutical & Biotechnology Companies, Academic & Government Institutes, Contract Research Organizations (CRO) and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 285: Argentina Historic Review for High Throughput Screening (HTS) by End-Use - Pharmaceutical & Biotechnology Companies, Academic & Government Institutes, Contract Research Organizations (CRO) and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 286: Argentina 16-Year Perspective for High Throughput Screening (HTS) by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Biotechnology Companies, Academic & Government Institutes, Contract Research Organizations (CRO) and Other End-Uses for the Years 2014, 2023 & 2030
  • BRAZIL
    • TABLE 287: Brazil Recent Past, Current & Future Analysis for High Throughput Screening (HTS) by Product Type - Consumables / Reagents, Consumables/Reagents, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 288: Brazil Historic Review for High Throughput Screening (HTS) by Product Type - Consumables / Reagents, Consumables/Reagents, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 289: Brazil 16-Year Perspective for High Throughput Screening (HTS) by Product Type - Percentage Breakdown of Value Sales for Consumables / Reagents, Consumables/Reagents, Instruments and Software & Services for the Years 2014, 2023 & 2030
    • TABLE 290: Brazil Recent Past, Current & Future Analysis for High Throughput Screening (HTS) by Technology - Cell-based Assay, Label-Free Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 291: Brazil Historic Review for High Throughput Screening (HTS) by Technology - Cell-based Assay, Label-Free Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 292: Brazil 16-Year Perspective for High Throughput Screening (HTS) by Technology - Percentage Breakdown of Value Sales for Cell-based Assay, Label-Free Technology and Other Technologies for the Years 2014, 2023 & 2030
    • TABLE 293: Brazil Recent Past, Current & Future Analysis for High Throughput Screening (HTS) by Application - Target Identification & Validation, Primary & Secondary Screening, Toxicology Assessment and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR